ArriVent's lead lung cancer drug firmonertinib fails Phase 3 trial, shares plunge

ArriVent BioPharma announced that its flagship EGFR inhibitor, firmonertinib, did not meet primary endpoints in a late-stage Phase 3 study for lung cancer. The trial results were released on October 6, 2026.

The failure marks a setback for the company, which has relied on a China licensing strategy to advance its pipeline. Analysts noted that the lack of efficacy data could delay any potential regulatory approval.

Following the announcement, ArriVent’s stock price fell sharply, reflecting investor concerns about the impact on future revenue and the broader pipeline.

The company has not disclosed next steps, but it may explore additional trials or alternative indications for the drug.